US Considers Insulin Cap, Trade Probe Over Drug Pricing

U.S. senators are pursuing legislation to cap insulin costs at $35 for individuals with private insurance and those who are uninsured. This initiative mirrors a provision in the 2022 tax-and-health care law that limited insulin costs for Medicare beneficiaries. Senator Susan Collins (R-Maine) is a key proponent of this new proposal, aiming to address affordability concerns ahead of her reelection campaign.

Separately, Switzerland's pharmaceutical industry trade group has indicated that the United States might initiate a trade investigation against the country, similar to one recently launched against Germany. This potential probe follows Germany's announcement in April of significant reforms to its statutory health care system, which include measures to reduce spending on pharmaceutical products. Such an investigation could lead to the U.S. imposing tariffs on German imports.

Switzerland is also currently evaluating its own healthcare policies, with proposed measures aimed at lowering mandatory health care prices. These potential reforms could result in reduced drug prices, a development that the pharmaceutical industry has voiced criticism against. The U.S. has previously launched Section 301 investigations into suspected unfair trade practices against numerous countries, which can result in retaliatory trade actions.